Oncotarget

Research Papers:

Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis

Zhen Qu, Junhua Wu, Junyi Wu, Anlai Ji, Guanghui Qiang, Yong Jiang _, Chunping Jiang and Yitao Ding

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:80666-80678. https://doi.org/10.18632/oncotarget.20881

Metrics: PDF 1298 views  |   HTML 2325 views  |   ?  


Abstract

Zhen Qu1,3,*, Junhua Wu2,*, Junyi Wu1,2, Anlai Ji4,5, Guanghui Qiang2,5, Yong Jiang3, Chunping Jiang1 and Yitao Ding1

1Department of Hepatobiliary Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, China

2Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu Province, China

3Department of Hepatobiliary Surgery, The First People's Hospital of Changzhou, The Third Hospital Affiliated to Soochow University, Changzhou, Jiangsu, China

4Department of General Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China

5Department of Hepatobiliary Surgery, Drum Tower Clinical College of Nanjing Medical University, Nanjing, Jiangsu Province, China

*These authors contributed equally to this work

Correspondence to:

Yong Jiang, email: yjiang8888@hotmail.com

Chunping Jiang, email: chunpingjiang@163.com

Yitao Ding, email: drdingyitao0@sina.com

Keywords: HCC, exosomal miRNA-665, biomarker, ERK, tumor growth

Received: April 13, 2017     Accepted: August 26, 2017     Published: September 14, 2017

ABSTRACT

Recent studies have shown that circulating microRNAs are potential biomarkers for various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs (miRNAs) as novel serological biomarkers for hepatocellular carcinoma (HCC) diagnosis and prognosis. Exosomes are small membranous vesicles (30–100 nm). Exosomal miR-665 levels in HCC patients were significantly higher than those in healthy subjects (P < 0.05), and exosomal miR-665 levels were significantly upregulated in tumours larger in size (> 5 cm), in tumours with local invasion and in those at an advanced clinical stage (stage III/IV) of HCC (P = 0.0042, 0.0197, and 0.0276, respectively). The survival time of the exosomal miR-665 high-expression group (n = 17) was significantly shorter than that of the low-expression group (n = 13) (P = 0.036). In addition, we found that HCC cell-derived exosomes promoted hepatoma cell proliferation and upregulated the expression level of proteins in the MAPK/ERK pathway in vitro and in vivo. This study suggests that serum exosomal miR-665 may be a novel minimally invasive biomarker for HCC diagnosis and prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20881